Characterization of disseminated tumor cells

Seminars in Surgical Oncology

Volumn 20, Issue 4, 2001, Pages 265-271

  Hosch, Stefan B ^a   Braun, Stephan ^b   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bone marrow; Double labeling; Lymph node; Minimal residual disease

Indexed keywords

NEU DIFFERENTIATION FACTOR;

BONE MARROW; CELL CLONE; CELL LABELING; DISSEMINATED CANCER; LYMPH NODE; METASTASIS; OCCULT CANCER; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

BONE MARROW NEOPLASMS; HUMANS; LYMPH NODES; NEOPLASM, RESIDUAL;

EID: 0034755460     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.1043     Document Type: Review

References (78)

1. Detection and clinical relevance of micrometastatic disease
2. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies
3. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow
4. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer
5. Micrometastases in bone marrow in patients with primary breast cancer: Evaluation as an early predictor of bone metastases
6. Prognostic importance of occult axillary lymph node micrometastases from breast cancers
7. Micrometastases to axillary lymph nodes from invasive lobular carcinoma of breast: Detection by immunohistochemistry and prognostic significance
8. Occult axillary node metastases in breast cancer: Their detection and prognostic significance
9. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
10. Identification of occult micrometastases in pericolic lymph nodes of Dukes' B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49
11. Clinical significance of occult micrometastasis in lymph nodes from patients with early gastric cancer who died of recurrence
12. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer
13. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non small cell lung cancer
14. Detection of occult metastases in lung carcinomas: Progress and implications for lung cancer staging
15. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer
16. Esophageal cancer: The mode of lymphatic tumor cell spread and its prognostic significance
17. Incidence of occult lymph node metastases in pathological stage C (pT3N0) prostate cancer
18. Implications of prostate micrometastases in pelvic lymph nodes: An archival tissue study
19. Early lymphatic tumor cell dissemination in pancreatic cancer: Frequency and prognostic significance
20. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study
21. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients
22. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients
23. Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer
24. The prognostic significance of marrow micrometastases in women with early breast cancer
25. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases
26. Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients
27. Monoclonal antibody LICR-LON-M8 does not predict the outcome of operable breast cancer
28. Comparative analyses of bone marrow micrometastases in breast and gastric cancer
29. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up
30. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
31. Can the presence of micrometastases in primary breast cancer predict outcome? Long-term (median 12.5 yrs) follow-up
32. Detection of cytokeratin 18-positive cells in bone marrow of breast cancer patients: No prediction of bad outcome
33. Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up
34. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy
35. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer
36. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery
37. Induction of tumor cell shedding into effluent venous blood during breast cancer surgery
38. Tumor antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease
39. Establishment of micrometastatic carcinoma cell lines: A novel source of tumor cell vaccines
40. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumor cells
41. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells
42. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells
43. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
44. Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase
45. Detection, characterization and tumorigenicity of tumor cells in human bone marrow
46. Studies of the HER-2/neu proto-oncogene in human breast cancer and ovarian cancer
47. Prognostic significance of c-erbB-2 expression in node negative breast cancer
48. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
49. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis
50. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis
51. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistochemical assessment correlates with gene amplification
52. Isolation of blood-borne epithelium derived c-erb-B2 oncoprotein-positive clustered cells from peripheral blood of breast cancer patients
53. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
54. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
55. Addition of Herceptin™ (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anti-cancer activity: A randomized, multinational controlled phase III trial
56. Phase II study of weekly intravenous recombinant humanized anti-p185Her2 monoclonal antibody in patients with Her2/neu-overexpressing metastatic breast cancer
57. Chromosomal aneusomies in prostate cancer marrow micrometastases
58. Low frequency epithelial cells in bone marrow from prostate carcinoma patients are cytogenetically aberrant
59. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells
60. Clinical importance of analysing malignant tumours of uncertain origin with immunohistological techniques
61. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancer
62. Regulation and functional role of MHC expression on tumors
63. Cell adhesion in invasion and metastasis
64. Molecular aspects of the metastatic cascade
65. Desmosomes and hemidesmosomes: Constitutive molecular components
66. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies
67. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: Establishment of working models for human micrometastases
68. Immunocytochemical detection of bone marrow micrometastasis in operable non-small cell lung cancer
69. Immunocytochemical detection of isolated tumor cells in bone marrow of patients with with untreated stage C prostatic cancer
70. Malignant phenotype of immunohistochemically detectable isolated tumor cells in lymph nodes of patients with esophageal cancer
71. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis
72. Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness
73. Unraveling the cytoplasmic interactions of the cadherin superfamily
74. Cell adhesion: The molecular basis of tissue architecture and morphogenesis
75. Tumorigenic potential of apparently tumor-free lymph nodes
76. Malignant potential and prognostic impact of occult disseminated tumor cells in patients with esophageal cancer
77. Standardisation of the immunocytochemical detection of cancer cells in bone marrow and blood. I. Establishment of objective criteria for the evaluation of immunostained cells
78. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up